INTRODUCTION
Coronavirus disease 2019 (COVID-19) is a SARS-CoV-2 infection that has spread rapidly since it was reported in Wuhan, China, in December 2019, and was declared a pandemic by the World Health Organization in March 2020. At the time of writing this manuscript, in August 2021, we are unfortunately facing the fifth wave of δ-mutant strains, and there are no prospects for containment. The purpose of this article is to introduce and share information on the acute neuromuscular manifestations and complications, sequelae, and adverse reactions after the COVID-19 vaccine that have been shown to date.

FREQUENCY AND CHARACTERISTICS OF NEUROMUSCULAR MANIFESTATIONS
The most characteristic symptom of COVID-19 is respiratory symptoms, but neuromuscular manifestations also occur frequently and might appear as the first symptom. The frequency of neuromuscular manifestations has been reported in China, Spain, Europe and the USA, ranging from 36.4% to 88.0%. Although olfactory and gustatory disturbances are characteristic of this disease, it should be noted that non-specific symptoms, such as headache, dizziness and muscle symptoms, are frequently observed (Table 1), and consciousness disturbance is common in severe cases. Neurological evaluation is essential when impairment of consciousness or psychiatric symptoms occur in the absence of hypoxemia or metabolic abnormalities.

NEUROMUSCULAR COMPLICATIONS
It has been reported that COVID-19 is associated with a variety of serious neuromuscular complications (Table 2), and that these complications worsen the prognosis. However, some of the evidence is based on a small number of case reports or case series, and the possibility that the complications occurred by chance at a time after
## Table 1: Frequency of neuromuscular symptoms

|                      | China (Ref.1) | Spain (Ref.2) | Europe (Ref.3) | Spain (Ref.4) | Chicago (Ref.5) |
|----------------------|---------------|---------------|----------------|---------------|-----------------|
| **Total no. patients** | 214           | 841           | Unknown (only patients with neurological symptoms were considered) | 100 (inpatients seen by neurologist) | 509             |
| **Proportion of patients presenting with neuromuscular symptoms (%)** | 36.4%          | 57.4%         | Unknown        | 88%           | 42.2% at onset  |
|                      |               |               |                |               | 62.7% at the time of hospitalization |
|                      |               |               |                |               | 82.3% at total course |
| **Types of neuromuscular symptoms (%)** |               |               |                |               |                 |
| muscle symptoms (20.3%) | 1. Dizziness (16.8%) | 2. Muscle symptoms (10.7%) | 3. Headache (13.1%) | 4. Consciousness disturbance (19.6%) | 5. Taste disorder (7.5%) |
| headache (14.1%) | 6. Smell disorder (5.1%) | 1. Headache (61.9%) | 2. Muscle symptoms (50.4%) | 3. Mmell disorder (49.2%) | 4. Taste disorder (39.8%) |
| muscle symptoms (20.3%) | 5. Dizziness (6.1%) | 6. Smell disorder (4.9%) | 7. Psychomotor symptoms (26.7%) | 8. Encephalopathy (21.0%) | 9. Stroke (21.0%) |
| 1. Headache (61.9%) | 2. Muscle symptoms (50.4%) | 3. Mmell disorder (49.2%) | 4. Taste disorder (39.8%) | 5. Dizziness (36%) | 6. Encephalopathy (8%) |
| 6. Smell disorder (4.9%) | 7. Psychomotor symptoms (26.7%) | 8. Encephalopathy (21.0%) | 9. Stroke (21.0%) | 10. Movement disorders (0.7%) | 11. Convulsions (2%) |
| 1. Headache (44%) | 2. Headache (44%) | 3. Muscle symptoms (43%) | 4. Dizziness (36%) | 5. Encephalopathy (8%) | 6. Syncope (7%) |
| 6. Smell disorder (2.5%) | 7. Psychomotor symptoms (26.7%) | 8. Encephalopathy (21.0%) | 9. Stroke (21.0%) | 10. Movement disorders (0.7%) | 11. Convulsions (2%) |
| 1. Muscle symptoms (44.8%) | 2. Headache (37.7%) | 3. Encephalopathy (31.8%) | 4. Dizziness (29.7%) | 5. Taste disorder (15.9%) | 6. Smell disorder (11.4%) |
the onset of COVID-19 cannot be ruled out. A proof of causality is required to confirm the epidemiological increase in the incidence and/or to elucidate the pathogenic mechanism.

### 3.1 | Cerebrovascular disease

In the cerebrovascular diseases associated with COVID-19, cerebral infarct is frequent. In addition, critical-illness microbleeds might occur due to disruption of the blood–brain barrier. In a meta-analysis of hospitalized patients in the USA, Canada and Iran, it was shown that the frequency of cerebrovascular diseases was 1.8% and in-hospital mortality was as high as 34.4%; the risk factors for in-hospital mortality were advanced age, comorbidity and severity of respiratory symptoms. In addition to atherosclerotic factors, such as hypertension, diabetes mellitus, dyslipidemia and obesity, severe COVID-19 has been shown to be a risk factor for developing the cerebrovascular disease. Another meta-analysis showed that the complication rate of cerebrovascular disease increased 4.2-fold in patients with severe COVID-19 compared with those without severe disease.

### 3.2 | Encephalitis and encephalopathy

There are at least three types of encephalitis/encephalopathy. The first is considered to be viral encephalitis caused by direct viral infection of the central nervous system (CNS). The second is encephalopathy, in which systemic inflammation (hypercytokinemia/cytokine storm) is followed by the rapid onset of neurological and psychiatric symptoms. The third is autoimmune encephalitis that develops after a certain period of time after COVID-19 infection and meets the diagnostic criteria for "possible autoimmune encephalitis" by Graus et al.

Evaluation of cytokines and chemokines might be distinguished by elevation in cerebrospinal fluid in encephalitis and in serum in encephalopathy. As encephalopathy and autoimmune encephalitis can be treated by immunotherapy, an appropriate diagnosis is required.

In addition, a number of encephalitis/encephalopathies with unique clinical and imaging findings have been reported. These include acute hemorrhagic necrotizing encephalitis, acute disseminated encephalomyelitis, mild encephalitis/encephalopathy with a reversible splenial lesion and posterior reversible encephalopathy syndrome.

### 3.3 | Multiple sclerosis/anti-myelin oligodendrocyte glycoprotein antibody-associated disease

A small number of patients with multiple sclerosis and anti-myelin oligodendrocyte glycoprotein antibody-associated disease have been reported after COVID-19 infection.

### 3.4 | Movement disorders and cerebellar ataxia

There are many reports of patients with myoclonus and opsoclonus-myoclonus syndrome after recovery from respiratory

### TABLE 2  Neuromuscular complications

| 1. Cerebrovascular diseases | Cerebral infarct  
| Venous sinus thrombosis  
| Critical illness-associated cerebral microbleeds |
| 2. Meningoencephalitis/encephalopathy | Meningoencephalitis  
| Steroid-responsive encephalitis/encephalopathy |
| 3. Other characteristic encephalopathies and encephalitis | Acute hemorrhagic necrotizing encephalopathy  
| Acute disseminated encephalomyelitis  
| Mild encephalitis and encephalopathy with reversible corpus callosum lesions  
| Posterior reversible encephalopathy syndrome |
| 4. Multiple sclerosis/anti-MOG antibody-related diseases | Myoclonus  
| Myoclonus-psychosomatic syndrome  
| Parkinsonism  
| Cerebellar syndrome |
| 5. Movement disorders/ataxia | Guillain–Barré syndrome, Miller Fisher syndrome, isolated facial nerve palsy  
| Sudden onset sensorineural hearing loss  
| Pressure neuropathy due to supine position |
| 6. Peripheral neuropathy | Myasthenia gravis  
| Acute myositis  
| Critical illness myopathy |
| 9. Adverse effects associated with COVID-19 treatment (remdesivir, favipiravir) | Headache, seizures, myoclonus, delirium, abnormal behavior, hallucinations, consciousness disturbance |

COVID-19, coronavirus disease 2019; MOG, myelin oligodendrocyte glycoprotein.
symptoms. In addition, acute onset of parkinsonism after infection and anti-amphiphysin antibody-positive cerebellar ataxia have been reported. As there have been reports of an increase in functional movement disorders in both adults and children after the pandemic, an appropriate diagnosis is necessary. 

3.5 | Peripheral neuropathy

In a systematic review of 18 cases of Guillain–Barré syndrome (GBS), the median time from COVID-19 onset to GBS onset was 10 days, and most patients presented with demyelinating GBS, with a prognosis of eight (44%) on artificial ventilators and two (11%) deaths. In a study in northern Italy, the incidence of GBS in March and April 2020 was reported to have increased 2.6-fold compared with the same period a year earlier.

Miller Fisher syndrome, isolated peripheral facial paralysis and sudden sensorineural hearing loss have also been reported. Furthermore, compression neuropathy caused by supine posture management, which is recommended for respiratory failure associated with acute respiratory distress syndrome, has also been reported. The most commonly injured nerves are the ulnar, radial, sciatic, brachial plexus and median nerves, in that order. It is necessary to avoid prolonged compression and extension of the elbow, upper arm, and shoulder.

3.6 | Neuromuscular junction disease

A few patients with the anti-acetylcholine receptor antibody or anti-muscle-specific tyrosine kinase-positive systemic myasthenia gravis have been reported within 5–7 days of COVID-19 onset.

3.7 | Muscle disorders

Patients with COVID-19 might present with myalgia and flaccid tetraplegia, hyperCKemia and abnormal muscle magnetic resonance imaging signals. A patient with a positive anti-small ubiquitin-like modifier 1 activation enzyme antibody specific for dermatomyositis and myopathological findings consistent with dermatomyositis has been reported, and the possibility that COVID-19-related myositis is dermatomyositis has been discussed. Although dermatomyositis is a type I interferonopathy in which type I interferon is involved in the pathogenesis, type I interferon, an antiviral cytokine induced by a viral infection, might cause dermatomyositis-like myositis. In severe cases, critical illness myopathy might be considered as a differential diagnosis.

3.8 | Neuromuscular manifestations associated with COVID-19 therapeutics

For remdesivir (Veklury), the adverse effects of headache, seizures, myoclonus, delirium and encephalopathy should be noted. For favipiravir (Avigan), the adverse effects of abnormal behavior, delirium, hallucinations, delusions, seizures and consciousness disturbance should be noted.

4 | PATHOGENESIS OF NEUROMUSCULAR COMPLICATIONS

The pathogenesis of the neuromuscular manifestations has been suggested to be a result of: (i) direct infection of the CNS; (ii) direct infection of cerebral blood vessels; (iii) disruption of the blood–brain barrier; (iv) thrombus formation; and (v) indirect neurological damage. First, direct infection of the CNS is thought to be mediated by the angiotensin-converting enzyme 2 receptor and the membrane protein, neuropilin-1. It has also been speculated that the SARS-CoV-2 virus spreads from the lungs and lower respiratory tract to the medulla oblongata through mechanoreceptors and chemoreceptors in a trans-synaptic manner. In fact, in human autopsy findings, viral proteins were found in the brainstem and lower cranial nerves, indicating that the virus can reach the brain. The ability of the SARS-CoV-2 virus to infect the brain (neuropotropism) has been confirmed by several methods, including infection experiments using transgenic mice expressing the human angiotensin-converting enzyme 2 receptor. However, there are some criticisms of the hypothesis that direct infection of the CNS is the primary pathogenesis, based on the fact that animal models are artificial and overexpress the human angiotensin-converting enzyme 2 receptor, and that viral RNA levels in the brains of most human patients are much lower than those in the nasal cavity.

With regard to direct infection of cerebral blood vessels, it has been reported that the SARS-CoV-2 virus is replicated in pericytes and can infect astrocytes. The disruption of the blood–brain barrier has been confirmed by analysis of cerebrospinal fluid findings in patients with encephalopathy, and by experiments using infected animals in which viral proteins were transferred to the brain. Regarding thrombus formation, it has been considered that coagulopathy in COVID-19 is similar to, but not identical to, sepsis-induced coagulopathy and disseminated intravascular coagulation syndrome, and that some features overlap with antiphospholipid antibody syndrome, hemophagocytic syndrome and thrombotic microangiopathy. The release of neutrophil extracellular traps, which is a known mechanism of intravascular thrombus formation in the antiphospholipid antibody syndrome, has also been confirmed, suggesting its involvement in the pathogenesis of the disease.

Finally, indirect neurological damage might be associated with systemic conditions, such as hypoxia, multiple organ failure, sepsis and shock. In addition, systemic hypercytokinemia (cytokine storm) might cause secondary neuroinflammation by disruption of the blood–brain barrier. It has also been shown that various autoantibodies, including an anti-hypocretin receptor antibody produced after infection may cause CNS disorders.
was reported to be 61 out of 159 (38%). In addition, the frequency of cognitive impairment 4 months after onset is an important problem, even in the younger generation.

16–30 age group, suggesting that cognitive impairment as a sequela of cognitive impairment was 18% in all age groups and 11% in the 4 to 12 weeks and the chronic phase thereafter. It presents with various symptoms, including fatigue, exercise intolerance, persistent low-grade fever, lymphadenopathy, hair loss, muscle weakness, arthralgia, dyspnea, cough, palpitations, chest pain, anxiety, depression, sleep disturbance and post-traumatic stress disorder. It also presents neuromuscular manifestations, including headache, brain fog, cognitive impairment and various autonomic disturbances (postural orthostatic tachycardia syndrome, temperature dysregulation, constipation and diarrhea).

Brain fog is a type of cognitive impairment that presents as a “foggy brain state”, and includes a lack of intellectual clarity, poor concentration, mental fatigue and anxiety. Several studies on cognitive impairment have been carried out. First, it was reported that cognitive impairment with frontal and parietal lobe dysfunction, and frontal and parietal hypometabolism on fluorodeoxyglucose positron emission tomography occurred in the subacute phase of patients hospitalized with COVID-19. In a study of hospitalized patients, the frequency of cognitive impairment 4 months after onset was reported to be 61 out of 159 (38%). In addition, the frequency of cognitive impairment was 18% in all age groups and 11% in the 16–30 age group, suggesting that cognitive impairment as a sequela is an important problem, even in the younger generation.

The following hypotheses have been proposed for the mechanism of brain fog and cognitive impairment. First, although the SARS-CoV-2 virus does not directly infect the CNS, microglial activation and abnormal mitochondrial function occur. Second, systemic inflammation crosses the blood-brain barrier and causes inflammation in the CNS, resulting in brain cell changes similar to those seen in neurodegenerative diseases, such as Alzheimer’s disease. Third, neuroinflammation after viral infection leads to aggregation of tau protein, resulting in neurodegeneration.

A recent review proposed that chronic neurological sequelae can be classified into four categories, including: (i) cognitive, mood and sleep disorders; (ii) dysautonomia; (iii) diverse pain syndrome; as well as (iv) marked exercise intolerance and fatigue, although more long-term follow-up studies are required. In any case, it is necessary to recognize that neuromuscular complications can occur even in mild cases and young people undergoing home treatment, and infection should be avoided as much as possible.

| Adverse reactions                                                                 | Vaccine          |
|-----------------------------------------------------------------------------------|------------------|
| Anaphylactic shock                                                                | All vaccines     |
| Vaccine-induced immune thrombocytopenia and cerebral venous thrombosis and cerebral hemorrhage | AstraZeneca      |
| Myocarditis and pericarditis in young patients                                    | Pfizer, Moderna |
| Bilateral facial nerve palsy                                                     | AstraZeneca      |
| Guillain–Barré syndrome                                                          | Johnson & Johnson|
| Encephalitis, opsoclonus myoclonus syndrome                                      | AstraZeneca      |
| Arterial thromboembolism                                                         | AstraZeneca      |

5 | POST-ACUTE COVID-19 SYNDROME

Long-lasting symptoms in patients recovering from an acute phase are called post-acute COVID-19 syndrome or post-acute sequelae of SARS-CoV-2 infection or long COVID/long-haul COVID. These are also the first diseases in history to be defined by patients themselves using social networking services (SNS), such as Twitter and Facebook. COVID-19 is referred to as the acute phase from onset to 4 weeks, the subacute phase from 4 to 12 weeks and the chronic phase thereafter. It presents with various symptoms, including fatigue, exercise intolerance, persistent low-grade fever, lymphadenopathy, hair loss, muscle weakness, arthralgia, dyspnea, cough, palpitations, chest pain, anxiety, depression, sleep disturbance and post-traumatic stress disorder. It also presents neuromuscular manifestations, including headache, brain fog, cognitive impairment and various autonomic disturbances (postural orthostatic tachycardia syndrome, temperature dysregulation, constipation and diarrhea).

Brain fog is a type of cognitive impairment that presents as a “foggy brain state”, and includes a lack of intellectual clarity, poor concentration, mental fatigue and anxiety. Several studies on cognitive impairment have been carried out. First, it was reported that cognitive impairment with frontal and parietal lobe dysfunction, and frontal and parietal hypometabolism on fluorodeoxyglucose positron emission tomography occurred in the subacute phase of patients hospitalized with COVID-19. In a study of hospitalized patients, the frequency of cognitive impairment 4 months after onset was reported to be 61 out of 159 (38%). In addition, the frequency of cognitive impairment was 18% in all age groups and 11% in the 16–30 age group, suggesting that cognitive impairment as a sequela is an important problem, even in the younger generation.

The following hypotheses have been proposed for the mechanism of brain fog and cognitive impairment. First, although the SARS-CoV-2 virus does not directly infect the CNS, microglial activation and abnormal mitochondrial function occur. Second, systemic inflammation crosses the blood-brain barrier and causes inflammation in the CNS, resulting in brain cell changes similar to those seen in neurodegenerative diseases, such as Alzheimer’s disease. Third, neuroinflammation after viral infection leads to aggregation of tau protein, resulting in neurodegeneration.

A recent review proposed that chronic neurological sequelae can be classified into four categories, including: (i) cognitive, mood and sleep disorders; (ii) dysautonomia; (iii) diverse pain syndrome; as well as (iv) marked exercise intolerance and fatigue, although more long-term follow-up studies are required. In any case, it is necessary to recognize that neuromuscular complications can occur even in mild cases and young people undergoing home treatment, and infection should be avoided as much as possible.
causality, an epidemiological increase in incidence and clarification of pathological mechanisms are required.

In addition, functional movement disorders after vaccines have also become a problem, as detailed on SNS. For example, “rapid-onset tic-like behavior” in young girls has been reported. It is characterized by predominance in young, severity and inducibility by unusual stimuli, as well as its spread through SNS. As these functional movement disorders also increase vaccine anxiety, it is necessary for healthcare providers to communicate appropriately with the general public to prevent a decline in vaccination rates and unnecessary expansion of the pandemic.

7 | CONCLUSION

In this article, I have detailed that COVID-19 can cause neuromuscular manifestations during the course of the disease and that the disease can start with neuromuscular manifestations. I have also detailed that COVID-19 can cause brain fog and cognitive impairment in patients of all ages, showing that the disease should be avoided, even by young people. I hope that the COVID-19 pandemic resolves, and the knowledge described here will no longer be necessary.

DISCLOSURE

The author declares no conflict of interest.

1. Approval of the research protocol: N/A
2. Informed Consent: N/A
3. Registry and the Registration No. of the study/trial: N/A
4. Animal Studies: N/A

ORCID

Takayoshi Shimohata https://orcid.org/0000-0002-8788-9089

REFERENCES

1. Mao L, Jin H, Wang M, Hu YU, Chen S, He Q, et al. Neurological manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77:1–9.
2. Romero-Sánchez CM, Díaz-Maroto I, Fernández-Díaz E, Sánchez-Larsen Á, Layos-Romero A, García-García J, et al. Neurologic manifestations in hospitalized patients with COVID-19: the ALBACOVID registry. Neurology. 2020;95:e1060–e670.
3. Moro E, Priori A, Beghi E, Helbok R, Campiglio L, Bassetti CL, et al. The international European Academy of Neurology survey on neuromuscular manifestations of COVID-19. Neurol Clin Pract. 2021;11:e64–e72.
4. García-Moncó JC, Cabrera Muras A, Erburo Iríarte M, Rodrigo Armenteros P, Collía Fernández A, Arranz-Martínez J, et al. Neurologic manifestations in a prospective unselected series of hospitalized patients with COVID-19. Neurol Clin Pract. 2021;11:e64–e72.
5. Liotta EM, Batra A, Clark JR, Shlobin NA, Hoffman SC, Orban ZS, et al. Frequent neurologic manifestations and encephalopathy-associated morbidity in Covid-19 patients. Ann Clin Transl Neurol. 2020;7:2221–30.
6. Oliveira V, Seabra M, Rodrigues R, Carvalho V, Mendes M, Pereira D, et al. Neuro-COVID frequency and short-term outcome in the Northern Portuguese population. Eur J Neurol. 2021;28:3360–8. https://doi.org/10.1111/ene.14874
7. Hernández-Fernández F, Sandoval Valencia H, Barbella-Aponte RA, Collado-Jiménez R, Ayo-Martín Ó, Barrena C, et al. Cerebrovascular disease in patients with COVID-19: neuroimaging, histological and clinical description. Brain. 2020;143:3089–103.
8. Cannac O, Martínez-Almoyna L, Hraiech S. Critical illness-associated cerebral microbleeds in COVID-19 acute respiratory distress syndrome. Neurology. 2020;95:498–9.
9. Fridman S, Bres Bullrich M, Jimenez-Ruiz A, Costantini P, Shah P, Just C, et al. Stroke risk, phenotypes, and death in COVID-19: systematic review and newly reported cases. Neurology. 2020;95:e337–e85.
10. Siepman T, Sedghi A, Simon E, Winzer S, Barlinn J, With K, et al. Increased risk of acute stroke among patients with severe COVID-19: a multicenter study and meta-analysis. Eur J Neurol. 2021;28:238–47.
11. Pezzini A, Padovani A. Lifting the mask on neurological manifestations of COVID-19. Nat Rev Neurol. 2020;16:636–44.
12. Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15:391–404.
13. Espindola OM, Gomes YCP, Brandão CO, Torres RC, Siqueira M, Soares CN, et al. Inflammatory cytokine patterns associated with neurological diseases in coronavirus disease 2019. Ann Neurol. 2021;89:1041–5.
14. Elkady A, Rabinstein AA. Acute necrotizing encephalopathy and myocarditis in a young patient with COVID-19. Neurology. 2020;70(5):e801
15. Paterson RW, Brown RL, Benjamin L, Nortley R, Wiethoff S, Bharucha T, et al. The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. Brain. 2020;143:3104–20.
16. Hayashi M, Sahashi Y, Baba Y, Okura H, Shimohata T. COVID-19-associated mild encephalitis/encephalopathy with a reversible splenial lesion. J Neurol Sci. 2020;415:116941.
17. Kishfy L, Casasola M, Banankhah P, Parvez A, Jan YJ, Shenoy AM, et al. Posterior reversible encephalopathy syndrome (PRES) as a neurological association in severe Covid-19. J Neurol Sci. 2020;414:116943.
18. Palao M, Fernández-Díaz E, Gracia-Gil J, Romero-Sánchez CM, Díaz-Maroto I, Segura T. Multiple sclerosis following SARS-CoV-2 infection. Mucol Sci Relat Disord. 2020;45:102377.
19. Pinto AA, Carroll LS, Nar V, Varatharaj A, Galea I. CNS inflammatory vasculopathy with antitimylin oligodendrocyte glycoprotein antibodies in COVID-19. Neurol Neuroimunflamm. 2020;7:e813.
20. Rábano-Suárez P, Bermejo-Guerrero L, Méndez-Guerrero A, Parra-Serrano J, Toledo-Alfocea D, Sánchez-Tejerina D, et al. Generalized myoclonus in COVID-19. Neurology. 2020;95:e767–e72.
21. Shah PB, Desai SD. Opsonocytolysis myoclonus ataxia syndrome in the setting of COVID-19 infection. Neurology. 2021;96:33.
22. Méndez-Guerrero A, Laespada-García MI, Gómez-Grande A, Ruiz-Ortiz M, Blanco-Palmero VA, Azcarate-Díaz FJ, et al. Acute hypokinetic-rigid syndrome following SARS-CoV-2 infection. Neurology. 2020;95:e2109–e18.
23. Oosthuizen K, Steyn EC, Tucker L, Ncube IV, Hardie D, Marais S. SARS-CoV-2 encephalitis presenting as a clinical cerebellar syndrome: a case report. Neurology. 2021;97:27–9.
24. Hull M, Parnes M, Jankovic J. Increased Incidence of Functional (Psychogenic) movement disorders in children and adults amidst the COVID-19 pandemic: a cross-sectional study. Neurol Clin Pract. 2021. https://doi.org/10.1212/CNP.00000000000001082
25. De Sanctis P, Doneddu PE, Viganò L, Selmi C, Nobile-Orazio E. Guillain-Barré syndrome associated with SARS-CoV-2 infection. A systematic review. Eur J Neurol. 2020;27:2361–70.
26. Filosto M, Cotti Piccinelli S, Gazzina S, Foresti C, Frigeni B, Servalli MC, et al. Guillain-Barré syndrome and COVID-19: an observational multicentre study from two Italian hotspot regions. J Neurol Neurosurg Psychiatry. 2021;92:751–6.

27. Gutiérrez-Ortiz C, Méndez-Guerrero A, Rodrigo-Rey S, San Pedro-Murillo E, Bermejo-Guerrero L, Gordo-Mañá R, et al. Miller Fisher syndrome and polyneuritis cranialis in COVID-19. Neurology. 2020;95:e601–e5.

28. Derollec C, Alberto T, Leri O, Mackowiak MA, Chen Y. Facial nerve palsy: an atypical clinical manifestation of COVID-19 infection in a family cluster. Eur J Neurol. 2020;27:2670–2.

29. Koupma FS, Forde CT, Manjaly JG. Sudden irreversible hearing loss post COVID-19. BMJ Case Rep. 2020;e238419.

30. Malik GR, Wolfe AR, Soriano R, Rydberg L, Wolfe LF, Deshmukh S, et al. Injury-prone: peripheral nerve injuries associated with prone positioning for COVID-19-related acute respiratory distress syndrome. Br J Anaesth. 2020;125:e478–e80.

31. Restivo DA, Centonze D, Alesina A, Marchese-Ragona R, Myasthenia gravis associated with SARS-CoV-2 infection. Ann Intern Med. 2020;173:1027–8.

32. Assini A, Gandoglia I, Damato V, Fuchs D, Hagberg L, Andersson LM, et al. COVID-19 treatments and pathogenesis including anosmia in patients with COVID-19. Sci Transl Med. 2020;12:eabd3876.

33. Zhang H, Charmchi Z, Seidman RJ, Anziska Y, Velayudhan V, Perk J. COVID-19-associated myositis may be dermomyositis. Neurology. 2020;95:e57–60.

34. Tanboon J, Nishino I. COVID-19-associated myositis may be dermatomyositis. Muscle Nerve. 2020;62:E57–60.

35. Zubair AS, McAlpine LS, Gardin T, Farhadian S, Evoli A, Del Sette M. COVID-19 associated with Myasthenia gravis. JAMA Neurol. 2020;77:1018–27.

36. Daly JL, Simonetti B, Klein K, Chen K-E, Williamson MK, Antón-Plágaro C, et al. Neuropilin-1 is a host factor for SARS-CoV-2 infection. Science. 2020;370:861–5.

37. Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV-2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol. 2020;92:552–5.

38. Matschke J, Lütgehetmann M, Hagel C, Sporhake JP, Schröder AS, Edler C, et al. Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. Lancet Neurol. 2020;19:919–29.

39. Zheng J, Wong LY, Li K, Verma AK, Ortiz ME, Warkentin TE, Thachil J, et al. COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice. Nature. 2021;589:603–7.

40. Thakur KT, Miller EH, Glendinning MD, Al-Dalahmah O, Banu MA, Boehme AK, et al. COVID-19 neuropathology at Columbia University Irving Medical Center/New York Presbyterian Hospital. Brain. 2021;awab148. https://doi.org/10.1093/brain/awab148

41. Wang LU, Sievert D, Clark AE, Lee S, Federman H, Gastfriend BD, et al. A human three-dimensional neural-perivascular ‘assembloid’ promotes astrocytic development and enables modeling of SARS-CoV-2 neuropathology. Nat Med. 2021;27:1600–6. https://doi.org/10.1038/s41591-021-01443-1

42. Edén A, Kanberg N, Gostner J, Fuchs D, Hagberg L, Andersson LM, et al. CSF biomarkers in patients with COVID-19 and neurologic symptoms: a case series. Neurology. 2021;96:e294–300.

43. Rhea EM, Logsdon AF, Hansen KM, Williams LM, Reed MJ, Baumann KK, et al. The S1 protein of SARS-CoV-2 crosses the blood-brain barrier in mice. Nat Neurosci. 2021;24:368–78.

44. Iba T, Levy JH, Connors JM, Warkentin TE, Thachil J, Levi M. The unique characteristics of COVID-19 coagulopathy. Crit Care. 2020;24:360.

45. Zuo YU, Estes SK, Ali RA, Gandhi AA, Yalavarthi S, Shi H, et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci Transl Med. 2020;12:eabd3876.

46. Yang AC, Kern F, Losada PM, Agam MR, Maat CA, Schmartz GP, et al. Dysregulation of brain and choroid plexus cell types in severe COVID-19. Nature. 2021;595:565–71.

47. Wang EY, Mao T, Klein J, Dai Y, Huck JD, Jaycox JR, et al. Diverse functional autoantibodies in patients with COVID-19. Nature. 2021;595:283–8.

48. Alwan NA. The road to addressing Long Covid. Science. 2021;373:491–3.

49. Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27:601–15.

50. Couzin-Frankel J. The long haul. Science. 2020;369:614–7.

51. Hosp JA, Dressing A, Blazhenets G, Bornmann T, Rau A, Schwabenland M, et al. Cognitive impairment and altered cerebral glucose metabolism in the subacute stage of COVID-19. Brain. 2021;144:1263–76.

52. Writing Committee for the COMEBC Study Group, Morin L, Savale L, Pham T, Colle R, Figueiredo S, et al. Four-month clinical status of a cohort of patients after hospitalization for COVID-19. JAMA. 2021;325(15):1525–34.

53. Blomberg B, Mohn K-I, Brokstad KA, Zhou F, Linchausen DW, Hansen B-A, et al. Long COVID in a prospective cohort of home-isolated patients. Nat Med. 2021;27:1607–13. https://doi.org/10.1038/s41591-021-01433-3

54. Stefano GB, Büttiker P, Weissenberger S, Martin A, Ptacek R, Kream RM. Editorial: the pathogenesis of long-term neuropsychiatric COVID-19 and the role of microglia, mitochondria, and persistent neuroinflammation: a hypothesis. Med Sci Monit. 2021;27:e933015.

55. Pratt J, Lester E, Parker R. Could SARS-CoV-2 cause tauopathy? Lancet Neurol. 2021;20:506.

56. Balcom EF, Nath A, Power C. Acute and chronic neurological disorders in COVID-19: potential mechanisms of disease. Brain. 2021:awab302. https://doi.org/10.1093/brain/awab302

57. Schultz NH, Servoll HI, Michelsen AE, Munthe LA, Lund-Johansen F, Ahlen MT, et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021;384:2124–30.

58. Johnson & Johnson Statement on COVID-19 Vaccine (7/12) (https://www.jnj.com/johnson-johnson-july-12-statement-on-COVID-19-vaccine

59. Allen CM, Ramsamy S, Tarr AW, Tighe PJ, Irving WL, Tanasecu R, et al. Guillain-Barré syndrome variant occurring after SARS-CoV-2 vaccination. Ann Neurol. 2021;90:315–8.

60. Zuhorn F, Graf T, Klingebiel R, Schäbitz WR, Rogalewski A. Postvaccinal encephalitis after ChAdOx1 nCoV-19. Ann Neurol. 2021;90:506–11. https://doi.org/10.1002/ana.26182

61. Pavord S, Scully M, Hunt BJ, Lester W, Bagot C, Craven B, et al. Clinical features of vaccine-induced immune thrombocytopenia and thrombosis. N Engl J Med. 2021;386:2124–30.

62. Johnson & Johnson Statement on COVID-19 Vaccine (7/12) (https://www.jnj.com/johnson-johnson-july-12-statement-on-COVID-19-vaccine

63. Huynh A, Kelton JG, Arnold DM, Daka M, Nazy I. Antibody epitopes in vaccine-induced immune thrombocytopenia and thrombosis. Nat Med. 2021;596(7873):565–569.

64. Lunn MP, Comblath DR, Jacobs BC, Querol L, van Doorn PA, Hughes RA, et al. COVID-19 vaccine and Guillain-Barré syndrome: let’s not leap to associations. Brain. 2021;144:357–60.

65. Hull M, Mered PM. Tics and TikTok: functional tics spread through social media. Mov Disord Clin Pract. 2021. https://doi.org/10.1002/mdc3.13267

66. Kim DD, Kung CS, Perez DL. Helping the public understand adverse events associated with COVID-19 vaccinations: lessons learned from functional neurological disorder. JAMA Neurol. 2021;78:789–90.